natgillin/translations-raw huggingface dataset:
The method of claim 1 wherein the maximum plant power, PMax(t), and/or the minimum plant power, PMin(t) are calculated through specific values of meteorological variables, such as wind speed, vw(t), and temperature, T(t), wherein the intermittent power generation plant is a wind turbine or wind farm. 
Metoda za kontrolu brzine napajanja koja minimizira zahtjeve za skladištenjem energije u povremenim postrojenjima za proizvodnju električne energije prema zahtjevu 1, naznačena time što se izračunavaju najveća snaga postrojenja, Pygx(t) i / ili minimalna snaga postrojenja, Pmin(t) putem specifičnih vrijednosti meteoroloških varijabli, poput brzine vjetra, v,(t) i temperatura, T(t), pri čemu je povremena elektrana za proizvodnju energije vjetrenjača ili vjetroolektrana.
Method according to claims 5-7, wherein the coating composition further comprises between 0.5% to 15% by weight of a seasoning agent, preferably a herb seasoning agent. 
Metoda prema zahtjevima 5-7, naznačeno time da sastav za premaz dalje sadrži 0,5% do 15% težinskog udjela začinskog agenta.
A process as claimed in claim 23, wherein the pamoic acid and AZD1152 hqpa are added at an initial ratio of 0.8 moles pamoic acid: 1 mole AZD1152 hqpa. 
Postupak prema zahtjevu 23, naznačen time da se pamoinska kiselina i AZD1152 hqpa dodaju u početnom omjeru od 0.8 mola pamoinske kiseline: 1 mol AZD1152 hqpa.
In a particular embodiment the formulation consists essentially of a suspension which comprises an admixture of a hydrophobic medium and a solid form wherein the solid form comprises a therapeutically effective amount of a therapeutic agent and about 10-20% preferably 15% medium chain fatty acid salt preferably sodium octanoate, and about 5-10% preferably 10% PVP-12; and wherein the hydrophobic medium comprises about 20-80%, preferably 30-70% triglyceride preferably glyceryl tricaprylate or glyceryl tributyrate or castor oil or a mixture thereof, about 3-10% surfactants, preferably about 6%, preferably glyceryl monocaprylate and Tween 80 and about 1% water; in particular embodiments the therapeutic agent is present at an amount of less than 33%, or less than 25%, or less than 10%, or less than 1% or less than 0.1%. 
Pripravak prema zahtjevima 1 do 15, naznačen time da sadrži 10-20%, poželjno 12-21%, poželjno 15% soli masne kiseline srednjeg lanca poželjno natrijevog oktanoata, 5-10%, poželjno 10% PVP-12, te pri čemu hidrofobni medij sadrži 20-80%, poželjno 30-70% triglicerida poželjno gliceril trikaprilat ili gliceril tributirat ili ricinusovo ulje ili njihovu smjesu, 3-10% surfaktanata, poželjno 6% gliceril monokaprilata i polioksietilen sorbitan monooleata i oko HR P20170929 T1 1% vode i pri čemu je oktreotid prisutan u količini od manje od 33%, ili manje od 25%, ili manje od 10 %, ili manje od 1% ili manje od 0.1%.
The bi-specific antibody of Claim 5, wherein the Fc fragment comprises an Fc region modified to reduce or eliminate one or more effector functions. 
Bispecifično protutijelo u skladu s patentnim zahtjevom 5, pri čemu Fc fragment obuhvaća Fc regiju modificiranu zbog smanjivanja ili uklanjanja jedne ili više efektorskih funkcija.
A pharmaceutical composition, comprising the polypeptide of any one of claims 1-10, the nucleic acid of claim 11, the nucleic acid expression vector of claim 12, and/or the recombinant host cell of claim 13, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija, koja sadrži polipeptid iz bilo kojeg od patentnih zahtjeva 1-10, nukleinsku kiselinu iz patentnog zahtjeva 11, ekspresioni vektor nukleinske kiseline iz patentnog zahtjeva 12, i/ili rekombinantnu stanicu domaćina 1z patentnog zahtjeva 13, i farmaceutski prihvatljiv nosač.
The apparatus according to one of Claims 1 to 4, characterized in that said apparatus comprises at least a second insulator, wherein said second insulator does preferably not contain a fermenter. 
Uređaj prema jednom od Zahtjeva 1 do 4, naznačen time da se uređaj sastoji od barem jednog dodatnog izolatora, pri čemu spomenuti izolator poželjno ne sadržava fermentor.
The pharmaceutical formulation of claim 3 or claim 4 further comprising an additional pharmaceutical agent. 
Formulacija za uporabu prema zahtjevima 4 do 15 koja nadalje sadrži dodatni farmaceutski agens, npr.
The fluid from which IL-18BP is purified is thus preferably cell culture supernatant, such as e.g. CHO-cell supernatant. 
HR P20070196 T3 koje se pročišćava IL-18BP stoga je poželjno supernatant stanične kulture poput primjerice supernatant kulture CHO stanica.
in part (i), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:131 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:130; 
(k) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 129i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 1285;
Aspect 9. The bispecific antibody of aspect 8, comprising a H/L chain combination of any one of aspects 1-7, and a H/L chain combination that binds a tumor-antigen. 
Bispecifično protutijelo sukladno patentnom zahtjevu 6, koje sadrži kombinaciju H/L lanca iz bilo kojeg od patentnih zahtjeva 1-5 i kombinaciju H/L lanca koja veže tumorski antigen.
Process according to claim 1, CHARACTERIZED in that in step (d) the acid is chosen from the group consisting of sulfuric acid, phosphoric acid, acetic acid, formic acid, trichloroacetic acid and carbonic acid, the temperature is between 20 and 70°C, the pressure is about 1 bar and that stoichiometric ratio of the acid to alkali of step (a) is approximately 1.05:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se u koraku (d) kiselina bira iz skupine koju čine sumporna kiselina, fosforna kiselina, octena kiselina, mravlja kiselina, trikloroctena kiselina i ugljična kiselina, temperatura je između 20 1 70%, tlak je otprilike 1 bar (100 kPa), a stehiometrijski omjer između kiseline 1 alkalije u koraku (a) je približno 1,05:1.
harvest the virus in cell culture supernatant and/or inside said cells. 
€) uzimanje virusa iz supernatanta stanične kulture i/ili unutrašnjosti tih stanica.
A pharmaceutical composition comprising (a) an Anabaena variabilis phenylalanine ammonia-lyase (AvPAL) variant, wherein the cysteine residues at positions 503 and 565 of said AvPAL variant have been substituted by serine residues (SEQ ID NO:11), and said AvPAL variant further comprises polyethylene glycol, wherein the ratio of the AvPAL variant and the polyethylene glycol is about 1:3, and (b) a pharmaceutically acceptable carrier comprising a stabilizer. The pharmaceutical composition of claim 1, wherein the stabilizer is L-phenylalanine or structural analog thereof. The pharmaceutical composition of claim 1, wherein the stabilizer is selected from the group consisting of L-phenylalanine, trans-cinnamic acid and benzoic acid. 
Farmaceutski sastav sadrži varijantu Anabaena variabilis fenilalanin amonij-liaze (AvPAL) i farmaceutski prihvatljivi nosač, pri čemu (1) AvPAL varijanta ima slijed SEQ ID NO: 10, gdje na poziciji 565 AvPAL varijanta ima serinski ostatak; ili (ii) AVvPAL varijanta ima slijed SEQ ID NO: 11, gdje na pozicijama 503 i 565 AvPAL varijanta ima serinski ostatak; i pri čemu farmaceutski prihvatljivi nosač sadrži stabilizator odabran iz grupe koja se sastoji od L-fenilalanina, trans-cimetne kiseline i benzojeve kiseline.
slowly introducing excess oxidant into the H3RuCl6 solution, stirring the H3RuCl6 solution for 0.5-1.5 hours to completely oxidize the H3RuCl6 solution to generate H2RuCl6, introducing excess NH4Cl into the H2RuCl6 solution, heating the H2RuCl6 solution to 60-90°C, stirring the H2RuCl6 solution for 1-3 hours, filtering the H2RuCl6 solution to obtain a filter cake, and washing the filter cake to obtain an (NH4)2RuCl6 solid, wherein the oxidant is soluble chlorate; and reducing the (NH4)2RuCl6 solid at a temperature of 450-800°C using a mixed gas of hydrogen and nitrogen to obtain ruthenium, wherein a volume fraction of the hydrogen in the mixed gas is 1-15%. 
5) polako uvođenje suviška oksidansa u otopinu HsgRuC1l, miješanje otopine H3RuC14 tijekom 0.5-1.5 sati kako bi se potpuno oksidirala otopina H3RuCl da se dobije H2RuCL, uvođenje suviška NH,CI u otopinu H>RuCL, zagrijavanje otopine H,RuCL na 60-90?C, uz miješanje otopine H,RuC1; tijekom 1-3 sata, filtriranje otopine H,RuCL kako bi se dobilo filterski kolač, i ispiranje filtarskog kolača kako bi se dobila krutina (NH,)»RuC1, pri čemu je oksidans topljivi klorat; i 6) reduciranje krutine (NH,)pRuCL pri temperaturi od 450-800*C upotrebom plinovite smjese vodika i dušika kako bi se dobilo rutenij, pri čemu volumni udio vodika u plinskoj smjesi iznosi 1-15%.
In any case, the knitting described above allows to obtain therapeutic hosiery items that are aesthetically very similar to conventional elegant hosiery items. 
U svakom slučaju, gore opisano pletenje omogućuje dobivanje terapeutskih čarapa koje su estetski vrlo slične konvencionalnim elegantnim čarapama.
Therefore, it is an object of the present invention to provide a method for preparing sustained release pharmaceutical composition comprising venlafaxine hydrochloride, wherein the form of venlafaxine is not changed in the course of the process even if the drug comes into contact with solvent, e.g. water, which causes the polymorphic change of the venlafaxine hydrochloride. 
HR P20080007 T3 Prema tome, cilj ovog izuma je osiguravanje postupak dobivanja farmaceutskog pripravka s produljenim otpuštanjem koji sadrži venlafaksin-hidroklorid, gdje se oblik venlafaksina ne mijenja tijekom postupka, čak i ako lijek dolazi u dodir s otapalom, primjerice vodom, što uzrokuje polimorfnu promjenu venlafaksin-hidroklorida.
Furthermore, according to the second and third embodiments of the invention, represented in tables 11 and 12, inulin is also used as a prebiotic, non digestible polysaccharide in the fibre composition. 
HR P20080437 T3 Nadalje, prema drugoj i trećoj varijanti, prikazanima u tablicama 11 i 12, u sastavini vlakana koristi se i inulin kao prebiotički, neprobavljivi polisaharid.
to rotate the drum, upon establishment of the open fall path, from the second rotary position to the third rotary position and move the element to the advanced position to forceably drive a returnable item received in the recess out of the recess and to the first output. 
Prema gore orijentirano skladište prema patentnom zahtjevu 13, naznačeno time, što je sredstvo (229) za ograničavanje udubljenja smješteno uz udubljenje i prilagođeno da spriječi bilo kakvo aksijalno pomicanje izvan dužine bubnja povratnog predmeta/artikla stavljenog u udubljenje.
In that case, the finishing disc will be entirely worn after smoothening the surface of five workpieces. 
U tom slučaju će disk za završnu obradu biti potpuno istrošen nakon izglađivanja površine pet komada koji se obrađuju.
FIG. 4 illustrates a system for implementing a rights management service in context of a user interface and playback device, according to one or more embodiments. 
Računalni sustav prema zahtjevu 8, gdje jedan ili više kontrolnih parametara kontroliraju dozvoljenu sekvencu korištenja skupa linkova za reprodukciju na uređaju za reprodukciju.
a C3-8 cycloalkyl-C1-6 alkyl group (wherein C3-8 cycloalkyl is optionally substituted by the same or different 1 to 5 substituents selected from the following group B); 
Cagcikloalkil-Cig4 alkil skupina (gdje Csa cikloalkil je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B);
According to a preferred embodiment, the pharmaceutical composition in form of emulsion or microemulsion is an oil-in-water emulsion or microemulsion. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 1, gdje je taj pripravak emulzija ili mikroemulzija ulje-u-vodi.
A method according to any preceding claim, wherein the skin has a simulated stone surface. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da omotač ima površinu koja oponaša kamenu površinu.
diphtheria toxoid; tetanus toxoid; 
(b) tetanusni toksoid;
The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutical composition comprises from 20 mg to 40 mg, preferably 30 mg, 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one. 
Farmaceutski sastav za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da farmaceutski sastav sadrži od 20 mg do 40 mg, prvenstveno 30 mg 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona.
Nutritional composition according to any one of the preceding claims comprising at least 0.1 wt.% arachidonic acid based on total fatty acids and the amount of arachidonic acid does not exceed 2.0 wt.% based on total fatty acids. 
Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva koji sadrži barem 0.1 tež.% arahidonske kiseline u odnosu na ukupne masne kiseline 1 količina arahidonske kiseline ne prelazi 2.0 tež.% u odnosu na ukupne masne kiseline.
In an embodiment, the ascorbate anion is provided by ascorbic acid, one or more salts of ascorbic acid selected from sodium ascorbate, potassium ascorbate, magnesium ascorbate and calcium ascorbate, or a mixture thereof. 
Otopina za čišćenje debelog crijeva prema zahtjevu 1 naznačena time da je askorbatni anion osiguran putem askorbinske kiseline, jedne ili više soli askorbinske kiseline koje su odabrane iz skupa koji čine natrijev askorbat, kalijev askorbat, magnezijev askorbat i kalcijev askorbat, ili njihova smjesa.
The composition of claim 1 or claim 2, wherein at least one amino acid is selected from the group consisting of alanine, 4-aminobutanoic acid, 3-aminopentanoic acid, 5-aminopentanoic acid, 6-aminohexanoic acid, 8-aminooctanoic acid, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, methyl lysine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. 
Pripravak prema zahtjevu 1 ili zahtjevu 2, naznačen time da barem jedna amino kiselina je amino kiselina koja je odabrana iz skupine koju čine alanin, 4-aminobutanska kiselina, 3-aminopentanska kiselina, 5-aminopentanska kiselina, 6-aminoheksanska kiselina, 8-aminooktanska kiselina, arginin, asparaginska kiselina, asparagin, cistein, glutaminska kiselina, glutamin, glicin, histidin, izoleucin, leucin, lizin, metionin, metil lizin, ornitin, fenilalanin, prolin, serin, treonin, triptofan, tirozin i valin.
wherein W is a halogen or a sulfonyl ester, and R15 is an amino-protecting group, to give a compound of formula VIII 
(VID, gdje je W halogen ili sulfonilni ester, a A2 i R15 su definirani kao u patentnim zahtjevima 6 ili 7, kako bi se dobilo spoj formule VIII.
The use of the system according to claim 1, wherein the solvent of the first composition is water. 
Upotreba sustava u skladu sa zahtjevom 1, naznačena time, što je otapalo prvog sastava voda.
A drug injection device of claim 8, wherein the lid has two first locking means arranged facing the inside of the main body case at opposite sides of the lid and the drug syringe mounting component has two corresponding second locking means. 
Uređaj za injektiranje lijeka prema zahtjevu 7, naznačen time što poklopac (11) ima dva prva sredstva za zaključavanje koja su postavljena prema unutrašnjosti glavnog tijela kućišta (10) na suprotnim stranama poklopca (11) i komponenta za postavljanje štrcaljke za lijek ima dva odgovarajuća druga sredstva za zaključavanje.
frequency locking to the universal reference signal; and 
- < zaključavanje frekvencije na spomenutom univerzalnom referentnom signalu; i
is hydrogen, unsubstituted or substituted C1-C2O alkyl, or unsubstituted or substituted aryl; and 
(1) Rs je vodik, nesupstituirani ili supstituirani C,-C2o-alkil, ili nesupstituirani ili supstituirani aril;
An isolated anti-Epidermal Growth Factor Receptor (EGFR) antibody for use in treating a tumor in a patient, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, and is conjugated to a cytotoxic agent. 
Izolirano protutijelo anti-EGFR (Epidermal Growth Factor Receptor)-(receptor epidermalnog faktora rasta), naznačeno time, da se upotrebljava u liječenju tumora kod ljudskog pacijenta, pri čemu protutijelo obuhvaća varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu pokazanu u SEQ ID NO:164, zatim obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu pokazanu u SEQ ID NO:166, te time, da je konjugirano na citotoksično sredstvo.
A compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, for use in the prevention and treatment of psychotic and neurodegenerative disorders. 
Spoj formule I prema bilo kojem zahtjevu 1 do 10, koji je u slobodnom bazičnom obliku ili u obliku farmaceutski prihvatljive dodatne kiselinske soli, naznačen time, da se upotrebljava za prevenciju i liječenje psihotičnih i neurodegenerativnih poremećaja.
The pharmaceutical composition for use according to claim 5, wherein the pharmaceutical composition comprises sodium hyaluronate or hyaluronic acid in the therapeutically effective concentration of 500-5,000 µg/mL. 
Farmaceutski oblik za uporabu prema zahtjevu 5, gdje farmaceutski oblik sadrži natrijev hijaluronat ili hijaluronsku kiselinu u terapijski učinkovitoj koncentraciji od 500-5,000 ug/mL.
Undefined terms have their art-recognized meanings. 
Nedefinirani izrazi imaju svoja uobičajena značenja iz struke.
The eye drop of claim 4, wherein the sodium hyaluronate or the hyaluronic acid is present at a concentration of 500-5,000 ug/mL. 
Farmaceutski oblik za uporabu prema zahtjevu 5, gdje farmaceutski oblik sadrži natrijev hijaluronat ili hijaluronsku kiselinu u terapijski učinkovitoj koncentraciji od 500-5,000 ug/mL.
An antibody or binding fragment thereof that binds human beta klotho, which comprises: (a) a heavy chain CDR1 comprising SEQ ID NO:1, a heavy chain CDR2 comprising SEQ ID NO:22, a heavy chain CDR3 comprising SEQ ID NO:3; and (b) a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. 
varijabilnu regiju teškog lanca koji sadrži CDR1 koji sadrži SEQ ID NO:13, CDR2 koji sadrži SEQ ID NO:14 i CDR3 koji sadrži SEQ ID NO:15; i varijabilnu regiju lakog lanca koji sadrži CDR1 koji sadrži SEQ ID NO:16, CDR2 koji sadrži SEQ ID NO:11 i CDR3 koji sadrži SEQ ID NO:17.
The immunogenic composition of claim 34, wherein the Hib capsular polysaccharide is conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što saharid Hib je konjugiran s proteinskim nosačem kojeg se bira iz skupine koju čine TT, DT, CRMI197, C fragment proteina TT, protein D, OMPC i pneumolizin.
The method of claim 1, wherein the solvent is a halogenated alkane solvent. 
Metoda iz bilo kojeg od prethodnih zahtjeva, naznačena time, što je otapalo halogenirani alkansko otapalo.
The method of embodiment 3, wherein the HLR is not associated with a specific physical network infrastructure for radio communication with subscribed devices. 
Postupak prema zahtjevu 3, pri čemu HLR nije povezan sa posebnom fizičkom mrežnom infrastrukturom za radio komunikaciju sa pretplatničkim uređajima.
The compound for use of claim 4 where the B-amyloid disease is Alzheimer's disease. 
Spoj za uporabu prema zahtjevu 4 naznačen time da B-amiloidna bolest je Alzheimerova bolest.
the heavy chain Fv fragment of a monovalent Fab forming the antigen-binding domain is linked to one of the polypeptides forming the Fc domain via a CH1 domain and the light chain Fv fragment of the Fab is linked to a CL domain; and the heavy chain Fv fragment of the Fab forming the CD3-binding domain is linked to the other polypeptide forming the Fc domain via a CH1 domain and the light chain Fv fragment of the Fab is linked to a CL domain; 
(1) Fv fragment teškog lanca jednovalentnog Fab koji tvori domenu za vezanje na antigen je vezan na jedan od polipeptida koji tvore Fc domenu preko domene CHI, a Fv fragment lakog lanca Fab je vezan na domenu CL; i Fv fragment teškog lanca Fab koji tvori domenu za vezanje na CD3 je vezan na drugi polipeptid koji tvori Fc domenu preko domene CHI, a Fv fragment lakog lanca Fab je vezan na domenu CL;
bortezomib (1.3 mg/m2) administered as a 3-5 second intravenous push on Days 15, 18, 22, and 25 (Cycle 1) and on Days 1, 4, 8, 11 (Cycle 2 and subsequent cycles); and 
bortezomib (1.3 mg/m2) administriran kao intravenski bolus od 3-5 sekundi na Dane 15, 18, 22, i 25 (Ciklus 1) i na Dane 1, 4, 8, 11 (Ciklus 2 i slijedeći ciklusi); i
The pharmaceutical composition according to claim 36, wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer. 
Farmaceutska kompozicija, antitijelo ili funkcionalni fragment prema patentnom zahtjevu 38, gdje rak je rak pluća, Tak dojke, rak prostate, rak gušterače, rak debelog crijeva, melanom, rak jetre, Tak jajnika, rak mjehura, rak trbuha, rak jednjaka, ili rak bubrega.
Method for controlling, analyzing and managing phases of conservation and/or processing of food in a mobile or fixed closed space, according to claim 6 characterized in that the measuring system of the pH in a food is integrated to the device object of the present invention, and that the calibration takes place by immersing the means of control of the pH measurement (10) in two solutions at known pH respectively at pH 7 and 4 so that the software can acquire the difference of the potential produced by the measuring probe of pH (10) at that given known value of the solution with known pH by determining the correct calibration of the curve of pH from 0 to 14 in the measuring integrated system of pH. 
Postupak kontroliranja, analiziranja i upravljanja fazama konzerviranja i/ili obrade hrane u pokretnom ili stacionarnom zatvorenom prostoru, u skladu s patentnim zahtjevom 6, naznačen time što sustav za mjerenje pH u hrani je integriran s uređajem kao predmetom predmetnog izuma, te što se kalibriranje provodi uranjanjem sredstva za kontroliranje mjerenja pH (10) u dvije otopine s poznatim pH i to pH 7 odnosno 4, tako da softver HR P20190734 T1 može dobiti razliku potencijala dobivenog sondom za mjerenje pH (10) kod one dane poznate vrijednosti otopine s poznatim pH određivanjem ispravnog kalibriranja krivulje pH od 0 do 14 u integriranom sustavu za mjerenje pH.
The according to claim 1, wherein the fixing comprises an operation for connecting, by gluing, heating, and pressing, the first gasket, made of waterproof polymeric material, to the assembly insole. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se navedena faza pričvršćivanja (101) sastoji od operacije kojom se lijepljenjem, grijanjem 1 prešanjem navedena prva brtva (16), izrađena od vodonepropusnog polimernog materijala, spaja na navedenu temeljnu tabanicu (15).
The following examples will further illustrate the invention. 
Slijedeći primjeri će dalje ilustrirati izum.
a plurality of rails (138A) being part of the framework (120), wherein the cage is slidable along the rails, and 
- < određenog broja vodilica (138A) koje su ugrađene u okvir (120), pri čemu se rešetka može pomicati po tim vodilicama, i -
The baked composition of claim 1, wherein said baked composition is selected from the group consisting of a bread, a cake, a cereal, a pie, a tart, a pastry, a candy bar, an energy bar, a granola bar, a quiche, a cookie, and a treat for companion animals. 
Pekarska kompozicija iz patentnog zahtjeva 1, gdje navedena pekarska kompozicija je odabrana iz grupe koja se sastoji od kruha, kolača, žitnih pahuljica, pite, tarta, peciva, slatkiš pločice, energetske pločice, granola pločice, kiša, kolačića, i poslastice za kućne ljubimce.